Orelabrutinib + R-CHOP

Phase 3Small molecule

BBeijing InnoCare Pharma Tech Co., Ltd.

Orelabrutinib + R-CHOP is one of 85 small molecule programs targeting Mantle Cell Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mantle Cell LymphomaActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Mantle Cell LymphomaPhase 3

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

332 competitors in Diffuse Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

39 2

Oncovin

Eli Lilly

Phase 3

34 3

Eloxatin

Teva

Phase 3

17 4

Rayos

RRoxane Laboratories

Phase 3

57 5

Cytosar

Teva

Phase 3

9 6

Adriamycin

GGynecologic Oncology Group

Phase 3

18 7

Actemra

Roche

Phase 3

5 8

Calquence

AstraZeneca

Phase 3

4 9

Afinitor

Novartis

Phase 3

3 10

Kesimpta

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Mantle Cell Lymphoma

NCT05051891

Clinical

Trials by Indication[1]

Mantle Cell Lymphoma1 trial

A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 3·NCT05051891·356 enrolled

Diffuse Large B-Cell Lymphoma1 trial

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma

Unknown status·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 3·NCT05234684·150 enrolled

Unspecified1 trial

DDI Study of Orelabrutinib

Completed·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 1·NCT05316857·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Orelabrutinib + R-CHOP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Orelabrutinib + R-CHOP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Orelabrutinib + R-CHOP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing InnoCare Pharma Tech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeijing InnoCare Pharma Tech Co., Ltd.

Orelabrutinib + R-CHOP

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Mantle Cell Lymphoma1 trial

Diffuse Large B-Cell Lymphoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News